Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Thyroid® · 2024
DOI: 10.1089/thy.2023.0363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thyroid®, 2024. Verfasst von Vivek Subbiah und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Anilides, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Rearranged during transfection ( RET ) alterations are targetable oncogenic drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study demonstrated clinical activity and manageable safety with pralsetinib, a selective RET inhibitor, in patients with advanced/metastatic RET -altered thyroid cancer. We present an updated analysis with more patients and longer follow-up.
Methods
Adult patients with advanced/metastatic RET -mutant medullary thyroid cancer (MTC) or RET fusion-positive thyroid cancer who initiated oral pralsetinib at 400 mg once daily were included. Primary endpoints were overall response rate (ORR) by blinded independent central review (per RECIST v1.1) and safety. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), and overall survival. Responses were assessed in three cohorts of patients with baseline measurable disease: patients with RET -mutant MTC who had received prior cabozantinib and/or vandetanib (C/V), treatment-naïve patients with RET -mutant MTC, and patients with previously treated RET fusion-positive thyroid cancer. Patient-reported outcomes (PROs) were an exploratory endpoint.
Results
As of October 18, 2021, the measurable disease population comprised of 61 patients with RET -mutant MTC and prior C/V, 62 treatment-naïve patients with RET -mutant MTC, and 22 patients with RET fusion-positive thyroid cancer who had received prior systemic therapy, including radioactive iodine. The ORR was 55.7% [confidence interval; 95% CI: 42.4–68.5] in patients with RET -mutant MTC and prior C/V, 77.4% [95% CI: 65.0–87.1] in treatment-naïve patients with RET -mutant MTC, and 90.9% [95% CI: 70.8–98.9] in patients with previously treated RET fusion-positive thyroid cancer. Median DoR and median PFS were both 25.8 months in patients with RET -mutant MTC and prior C/V, not reached in treatment-naïve patients with RET -mutant MTC, and 23.6 and 25.4 months, respectively, in patients with previously treated RET fusion-positive thyroid cancer. In the RET -altered thyroid cancer safety population ( N = 175), 97.1% of patients reported a treatment-related adverse event (TRAE); these led to discontinuation in 5.7% and dose reduction in 52.6% of patients. There was one death (0.6%) due to a TRAE. PROs improved or remained stable after pralsetinib treatment.
Conclusions
In this updated analysis of the ARROW study, pralsetinib continued to show deep and durable clinical activity and a manageable safety profile in patients with advanced/metastatic RET- altered thyroid cancer. Clinical Trial Registration: NCT03037385
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
- Developmental Cancer Therapeutics Laboratory, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA.
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Department of Medicine, University of California Irvine, Orange, California, USA.
ORCID-Profile: Vivek Subbiah, Julien Hadoux
Zitieren
APA
Subbiah, V., Hu, M. I., Mansfield, A. S., Taylor, M. H., Schuler, M., Zhu, V. W., Hadoux, J., Curigliano, G., Wirth, L., Gainor, J. F., Alonso, G., Adkins, D., Godbert, Y., Ahn, M. J., Cassier, P. A., Cho, B. C., Lin, C. C., Zalutskaya, A., Barata, T., …, & Brose, M. S. (2024). Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid®. https://doi.org/10.1089/thy.2023.0363
Vancouver
Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, et al. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid®. 2024. doi:10.1089/thy.2023.0363
BibTeX
@article{Subbiah2024,
author = {Subbiah, Vivek and Hu, Mimi I and Mansfield, Aaron S and Taylor, Matthew H and Schuler, Martin and Zhu, Viola W and Hadoux, Julien and Curigliano, Giuseppe and Wirth, Lori and Gainor, Justin F and Alonso, Guzman and Adkins, Douglas and Godbert, Yann and Ahn, Myung-Ju and Cassier, Philippe A and Cho, Byoung Chul and Lin, Chia-Chi and Zalutskaya, Alena and Barata, Teresa and Trask, Peter and Scalori, Astrid and Bordogna, Walter and Heinzmann, Sebastian and Brose, Marcia S},
title = {Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study},
journal = {Thyroid®},
year = {2024},
doi = {10.1089/thy.2023.0363}
}
EUVIMED